Minimal structural elements of an inhibitory anti-ATF1/CREB single-chain antibody fragment (scFv41.4)

R. J. Olsen, J. Mazlo, Scott A Koepsell, T. W. McKeithan, Steven Heye Hinrichs

Research output: Contribution to journalArticle

2 Citations (Scopus)

Abstract

Antibody variable domains represent potential structural models for the rational design of therapeutic molecules that bind cellular proteins with high affinity and specificity. The Activating Transcription Factor 1 (ATF1)/Cyclic AMP Response Element Binding Protein (CREB) family of transcription factors are particularly relevant targets due to their strong association with melanoma and clear cell sarcoma. Biochemical and structural investigations were performed to optimize a single-chain antibody fragment (scFv), scFv41.4, that disrupts the binding of ATF1/CREB to cyclic-AMP response elements (CRE) in vitro and inhibits transcriptional activation in cells. Molecular modeling and ligand docking simulations suggested that scFv41.4 could function as a disulfide-deficient single domain scFv. Functional studies verified that deletion of the light chain did not result in reduced inhibitory activity. The isolated heavy chain was predicted to assume a relaxed structural conformation that maintained a functional antigen binding pocket. The minimal structural elements necessary for intracellular function were further analyzed by selective deletion of CDR1 and CDR2. VH-CDR1 and VH-CDR3 were shown to play a key role in antigen binding activity, but VH-CDR2 was dispensable. Thus, scFv41.4 represents a unique molecule with potential for use in the design of peptidomimetic derivatives having therapeutic application to human cancer.

Original languageEnglish (US)
Pages (from-to)65-77
Number of pages13
JournalHybridoma and Hybridomics
Volume22
Issue number2
DOIs
StatePublished - Apr 2003

Fingerprint

Activating Transcription Factor 1
Cyclic AMP Response Element-Binding Protein
Single-Chain Antibodies
Immunoglobulin Fragments
Clear Cell Sarcoma
Peptidomimetics
Antigens
Structural Models
Response Elements
Disulfides
Cyclic AMP
Transcriptional Activation
Melanoma
Transcription Factors
Ligands
Light
Antibodies
Therapeutics
Neoplasms
Proteins

ASJC Scopus subject areas

  • Immunology
  • Genetics

Cite this

Minimal structural elements of an inhibitory anti-ATF1/CREB single-chain antibody fragment (scFv41.4). / Olsen, R. J.; Mazlo, J.; Koepsell, Scott A; McKeithan, T. W.; Hinrichs, Steven Heye.

In: Hybridoma and Hybridomics, Vol. 22, No. 2, 04.2003, p. 65-77.

Research output: Contribution to journalArticle

@article{9d9a61d3c5e34880ac9b717f6cfb4fb1,
title = "Minimal structural elements of an inhibitory anti-ATF1/CREB single-chain antibody fragment (scFv41.4)",
abstract = "Antibody variable domains represent potential structural models for the rational design of therapeutic molecules that bind cellular proteins with high affinity and specificity. The Activating Transcription Factor 1 (ATF1)/Cyclic AMP Response Element Binding Protein (CREB) family of transcription factors are particularly relevant targets due to their strong association with melanoma and clear cell sarcoma. Biochemical and structural investigations were performed to optimize a single-chain antibody fragment (scFv), scFv41.4, that disrupts the binding of ATF1/CREB to cyclic-AMP response elements (CRE) in vitro and inhibits transcriptional activation in cells. Molecular modeling and ligand docking simulations suggested that scFv41.4 could function as a disulfide-deficient single domain scFv. Functional studies verified that deletion of the light chain did not result in reduced inhibitory activity. The isolated heavy chain was predicted to assume a relaxed structural conformation that maintained a functional antigen binding pocket. The minimal structural elements necessary for intracellular function were further analyzed by selective deletion of CDR1 and CDR2. VH-CDR1 and VH-CDR3 were shown to play a key role in antigen binding activity, but VH-CDR2 was dispensable. Thus, scFv41.4 represents a unique molecule with potential for use in the design of peptidomimetic derivatives having therapeutic application to human cancer.",
author = "Olsen, {R. J.} and J. Mazlo and Koepsell, {Scott A} and McKeithan, {T. W.} and Hinrichs, {Steven Heye}",
year = "2003",
month = "4",
doi = "10.1089/153685903321947987",
language = "English (US)",
volume = "22",
pages = "65--77",
journal = "Monoclonal Antibodies in Immunodiagnosis and Immunotherapy",
issn = "2167-9436",
publisher = "Mary Ann Liebert Inc.",
number = "2",

}

TY - JOUR

T1 - Minimal structural elements of an inhibitory anti-ATF1/CREB single-chain antibody fragment (scFv41.4)

AU - Olsen, R. J.

AU - Mazlo, J.

AU - Koepsell, Scott A

AU - McKeithan, T. W.

AU - Hinrichs, Steven Heye

PY - 2003/4

Y1 - 2003/4

N2 - Antibody variable domains represent potential structural models for the rational design of therapeutic molecules that bind cellular proteins with high affinity and specificity. The Activating Transcription Factor 1 (ATF1)/Cyclic AMP Response Element Binding Protein (CREB) family of transcription factors are particularly relevant targets due to their strong association with melanoma and clear cell sarcoma. Biochemical and structural investigations were performed to optimize a single-chain antibody fragment (scFv), scFv41.4, that disrupts the binding of ATF1/CREB to cyclic-AMP response elements (CRE) in vitro and inhibits transcriptional activation in cells. Molecular modeling and ligand docking simulations suggested that scFv41.4 could function as a disulfide-deficient single domain scFv. Functional studies verified that deletion of the light chain did not result in reduced inhibitory activity. The isolated heavy chain was predicted to assume a relaxed structural conformation that maintained a functional antigen binding pocket. The minimal structural elements necessary for intracellular function were further analyzed by selective deletion of CDR1 and CDR2. VH-CDR1 and VH-CDR3 were shown to play a key role in antigen binding activity, but VH-CDR2 was dispensable. Thus, scFv41.4 represents a unique molecule with potential for use in the design of peptidomimetic derivatives having therapeutic application to human cancer.

AB - Antibody variable domains represent potential structural models for the rational design of therapeutic molecules that bind cellular proteins with high affinity and specificity. The Activating Transcription Factor 1 (ATF1)/Cyclic AMP Response Element Binding Protein (CREB) family of transcription factors are particularly relevant targets due to their strong association with melanoma and clear cell sarcoma. Biochemical and structural investigations were performed to optimize a single-chain antibody fragment (scFv), scFv41.4, that disrupts the binding of ATF1/CREB to cyclic-AMP response elements (CRE) in vitro and inhibits transcriptional activation in cells. Molecular modeling and ligand docking simulations suggested that scFv41.4 could function as a disulfide-deficient single domain scFv. Functional studies verified that deletion of the light chain did not result in reduced inhibitory activity. The isolated heavy chain was predicted to assume a relaxed structural conformation that maintained a functional antigen binding pocket. The minimal structural elements necessary for intracellular function were further analyzed by selective deletion of CDR1 and CDR2. VH-CDR1 and VH-CDR3 were shown to play a key role in antigen binding activity, but VH-CDR2 was dispensable. Thus, scFv41.4 represents a unique molecule with potential for use in the design of peptidomimetic derivatives having therapeutic application to human cancer.

UR - http://www.scopus.com/inward/record.url?scp=0037835862&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=0037835862&partnerID=8YFLogxK

U2 - 10.1089/153685903321947987

DO - 10.1089/153685903321947987

M3 - Article

C2 - 12831531

AN - SCOPUS:0037835862

VL - 22

SP - 65

EP - 77

JO - Monoclonal Antibodies in Immunodiagnosis and Immunotherapy

JF - Monoclonal Antibodies in Immunodiagnosis and Immunotherapy

SN - 2167-9436

IS - 2

ER -